Medical technology company Sky Medical wins prestigious King's Award for business innovation due to geko device
Geko Device by Sky Medical Technology Transforms Wound Care and Thrombosis Prevention
The Geko device, manufactured by Sky Medical Technology Ltd, is making waves in the medical field as a breakthrough solution for chronic wound care and thrombosism prevention. This innovative device has recently received regulatory approval in Japan, marking a significant milestone in its global expansion [1].
The Geko device utilises neuromuscular electrostimulation to improve blood flow, promoting healing and reducing the risk of clots in patients with circulatory problems. This feature positions it as a promising alternative or complement to conventional therapies for chronic wounds and venous thromboembolism (VTE) prevention [1].
Sky Medical is actively promoting the adoption of the Geko device through clinical partnerships and by enhancing its team with new leadership in wound care therapy to expand market presence [1]. The device's impact is evident in its growing acceptance, with the number of prescriptions for the Geko device increasing by over 60% quarter-over-quarter for the last three consecutive quarters [1].
The Geko device's portability and simplicity are reducing demand on overstretched healthcare services and lowering the carbon footprint associated with frequent in-person visits and complex compression dressing changes. By increasing lower limb blood flow, the device leads to shorter treatment cycles, lower care costs, and enhanced patient adherence [1].
Clinicians are reporting an immediate reduction in pain associated with the use of the Geko device, and patient-reported benefits are drawing particular attention in clinical settings. The adoption of the Geko device is escalating across multiple NHS primary care clinics, and with FDA clearance, NICE guidance, and integration across NHS Trusts and international health systems, the company claims the Geko device is establishing a new standard in chronic wound management [1].
Recently, Sky Medical Technology was awarded the King's Award for Enterprise in Innovation for its breakthrough wound care technology, the Geko device. This recognition is given only to the UK's most forward-thinking and high-performing businesses [1]. Fiona Young, Firstkind Wound Therapy Business Director, commented that the Geko device delivers real-world value clinically, operationally, and economically [1].
Chronic wounds remain a critical global health challenge, costing healthcare systems billions annually. The rapid effect on healing observed with the use of the Geko device could potentially revolutionise the way these wounds are managed [1]. As of mid-2025, the Geko device is progressing steadily in global markets with regulatory approvals, increasing clinical adoption, and recognised potential to transform wound care and thrombosis prevention [1].
[1] Source: Sky Medical Technology Ltd press releases and company reports.
- The Geko device, a product of Sky Medical Technology, uses medical-grade plastics and science-backed technology to influence blood flow and contribute to patient care, making it a promising alternative or complementary solution for chronic wound care and thrombosis prevention.
- The Geko device, with its focus on health-and-wellness and advanced technology, has been embraced by clinicians and healthcare providers, resulting in a significant increase in prescriptions and a growing acceptance, particularly in the UK's National Health Service (NHS) clinics.
- As innovation in science and technology is key to addressing medical-conditions like chronic wounds, the Geko device's capacity to reduce treatment cycles, lower care costs, and enhance patient adherence, while minimizing healthcare service demand and carbon footprint, underscores its potential to revolutionize the field of health-and-wellness and patient care.
